Sponsored symposia
Exclusive Symposium 1: 14:30 - 15:45 (UTC), Monday, June 21
Bayer AG
SY01: Tumor Agnostic Medicines for Rare Genomic Alterations: Meeting the HTA and Market Access Challenges
In the era of precision medicine, there has been a shift from organ-based to tumor-agnostic anti-cancer platforms. The recent regulatory approval of tumor-agnostic drugs for patients with rare tropomyosin recepter kinase (TRK) fusion cancer signals the emergence of more novel therapies, based on molecular profiling that allows identification of specific oncogenic drivers and predictive biomarkers of therapeutic efficacy. While experts agree that randomized clinical trials (RCTs) are not possible for such therapies, and strategies for clinical trial design, outcomes selection, and comparative value assessments are evolving, challenges remain to achieving access.
This symposium will highlight the value of precision oncology medicines (POMs) and tumor-agnostic drugs (TADs), evaluate response rate as an alternative endpoint for economic modeling (e.g., when overall survival [OS] is unavailable), and discuss considerations and challenges when comparing highly selective versus multi-targeted POMs/TADs.
Exclusive Symposium 3: 10:15 - 11:30 (UTC), Tuesday, June 22
Takeda UK, Limited
SY03: Giving Caregivers a Clear Voice in HTA
Informal caregivers sacrifice their time and wellbeing to care for patients. Within current HTAs, informal caregivers’ perspectives too frequently go unheard. Our symposium will explore why caregiver quality of life is an important consideration, look at how it is considered in HTAs globally and discuss how it could be more universally included, including how industry capture the necessary data.
Symposia Session 1: 14:00 - 15:00 (UTC), Tuesday, June 22
Janssen
SS01: Evolving HTA Frameworks to Keep Pace with Cancer Innovation and Accelerate Access for Patients
Despite significant scientific advances, patients still face delays in accessing novel cancer therapies. While overall survival has historically been the critical measure for assessing benefit, improved efficacy of new therapies often means this is no longer feasible.
Within this context, this symposium will explore collaborative solutions aimed at achieving sustainable access for patients to cancer innovations across Europe.
Novartis Pharma AG
SS02: Converging Novel HTA and Access Pathways in Adaptable Healthcare Systems
Innovative health technologies have the potential to transform healthcare systems. Existing HTA frameworks often fail to evaluate complexity of these advances. Adaptive frameworks and disruptive launch models may have the ability to address healthcare needs. One of the key elements of adaptive HTAs should be the development of innovative multi-stakeholder collaborative networks of healthcare scientists, suppliers, telecommunication companies, policy makers, etc. for innovations to flourish and spread at scale, thus accelerating countries' progress on health-related priorities. The symposium explores stakeholder perspectives on disconnects between innovation and HTA frameworks and aims to discuss feasible pathways to healthcare system shaping through innovation.
Pfizer UK
SS03: What role might Outcomes-Based Agreements for Medicines play in future Value-Based Healthcare Systems?
Value Based Healthcare (VBHC) has offered health systems a new operating framework driven by outcomes that matter to patients and where reimbursement and payment require a degree of demonstrated value in a real-world setting. However, delivering on the aspirations of VBHC is challenging and implementing innovative schemes, such as outcomes-based agreements (OBAs) in this context requires a whole system shift. This symposium will discuss the role of OBAs in future VBHC systems and some of the challenges that these will need to overcome to become a reality; from defining the outcomes that add value, to establishing the right data infrastructures to systematically collect these in the long-term. The session will bring together diverse perspectives of how this could happen, from patients, healthcare professionals, through to reimbursement bodies, payers and industry partners.
Exclusive Symposium 4: 10:15 - 11:30 (UTC), Wednesday, June 23
VIfor Pharma
SY04: From NYHA to KCCQ: A Novel Approach to Cost-effectiveness Analysis in Heart Failure (the AFFIRM-AHF Case Study)
Heart failure (HF) is a debilitating condition associated with morbidity, mortality, rehospitalization risk and high healthcare costs, in which concomitant iron deficiency is associated with worse prognosis. HF symptoms are typically measured using NYHA classes. KCCQ is a questionnaire that provides a patient-centric assessment of HF-specific health status. The Symposium will discuss the advantages and disadvantages of NYHA vs KCCQ , when applied to cost-effectiveness analyses of the recent AFFIRM-AHF trial, which included patients with iron deficiency after an acute HF episode.
Specifically, to make economic evidence available when allocating resources, measurement and estimation of outcomes are pivotal for correctly assess a new intervention. Transparently reporting a broader extent of outcomes on top of the functional one (NYHA class) can be of interest of the assessors to better value the money they are going invest in a new health technology. Consequently, this can be inspiring as new method for estimating outcomes, also for other clinical conditions and areas.
Symposia Session 3: 19:30 - 20:30 (UTC), Wednesday, June 23
Merck & Co. Ltd
SS04: How Regulatory Bodies and HTA Agencies can Collaborate to Foster Timely Patient Access to Transformative Innovation
The audience will gain greater understanding of the current opportunities and limitations in the regulatory and HTA interface, and how we can optimize this to address future HTA challenges whilst enabling timely patient access.